The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented...
Hence then, the article about co diagnostics inc announces intention to submit enhanced version of covid 19 test to fda for 510 k clearance was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance )
Also on site :
- Eightco Holdings (NASDAQ : ORBS) annonce un total d'environ 406 millions de dollars en avoirs, dont OpenAI, Beast Industries, plus de 16 000 ETH et plus de 283 millions de tokens WLD
- HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
- The No.1 Commodity Story of the Year Is Flying Under Wall Street’s Radar